Publication Name	World Journal of Hepatology
Manuscript ID	4424
Country	Greece

Received	2013-06-29 18:41
Peer-Review Started	2013-06-29 20:43
First Decision by Editorial Office Director
Return for Revision	2013-08-08 17:54
Revised	2013-07-24 06:44
Publication Fee Transferred
Second Decision by Editor	2013-08-19 12:29
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2013-08-20 00:27
Articles in Press
Edit the Manuscript by Language Editor
Typeset the Manuscript	2013-09-03 08:41
Publish the Manuscript Online	2013-10-01 17:51

ISSN	1948-5182 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Medicine, General & Internal
Manuscript Type	Review
Article Title	Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease
Manuscript Source	Invited Manuscript
All Author List	Michael S Kostapanos, Anastazia Kei and Moses S Elisaf
Funding Agency and Grant Number
Corresponding Author	Moses S Elisaf, MD, FRPSH, FASA, Professor of Medicine, Department of Internal Medicine, School of Medicine, University of Ioannina, St. Niarchou Avenue, 45110 Ioannina, Greece. egepi@cc.uoi.gr
Key Words	Fenofibrate; Non-alcoholic fatty liver disease; Steatohepatitis; Peroxisome proliferator-activated receptors
Core Tip	Non-alcoholic fatty liver disease (NAFLD) is a common health problem associated with increased liver- and vascular-specific complications. Dyslipidemia, predominantly hypertriglyceridemia, and insulin resistance play a key role in its pathogenesis. Fenofibrate, by activating peroxisome proliferator-activated receptors appears to decrease liver steatosis in experimental animal studies. This benefit can be attributed to its lipid-lowering potency, together with anti-inflammatory and anti-oxidant actions. Also, fenofibrate increases adiponectin levels and the expression of its liver-active receptor. A potential protective role of fenofibrate against NAFLD has also been implied by few small clinical studies. However, this benefit should be further assessed.
Publish Date	2013-10-01 17:51
Citation	Kostapanos MS, Kei A, Elisaf MS. Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease. World J Hepatol 2013; 5(9): 470-478
URL	http://www.wjgnet.com/1948-5182/full/v5/i9/470.htm
DOI	http://dx.doi.org/10.4254/wjh.v5.i9.470

Full Article (PDF)	WJH-5-470.pdf
Manuscript File	4424-Review.docx
Answering Reviewers	4424-Answering reviewers.pdf
Copyright License Agreement	4424-Copyright assignment.pdf
Peer-review Report	4424-Peer reviewer(s).pdf
Scientific Editor Work List	4424-Scientific editor work list.doc